Takeda concludes EAMEA Oncology Summit in Cairo, reinfor

Cairo, Egypt, February 2026:

Takeda, the patient-focused global biopharmaceutical company, successfully concluded the EAMEA Oncology Summit in Cairo under the theme “A Vision for Regional Excellence”, bringing together leading oncologists and regional and international experts to exchange scientific insights aimed at improving patient outcomes across diverse healthcare systems in the EAMEA region.

The two-day summit brought together leading experts for scientific discussions and interactive sessions focused on key topics in oncology care.

Experts shared insights on evolving clinical approaches in the management of Haematological Malignancies including considerations for advanced and refractory cases.

Sessions also addressed updates in the continuum care of cancer, reflecting varied disease stages.

These expert-led discussions aimed to support ongoing medical education, encourage knowledge exchange, and foster alignment of clinical practices across the region.

Khaled Sary, General Manager, Takeda West Gulf Cluster and Egypt, emphasized the summit’s role in driving progress:

“This summit provides an important platform for healthcare professionals across the EAMEA region to exchange scientific insights and share clinical perspectives.

By facilitating such discussions, we aim to support knowledge-sharing and alignment on evolving practices in oncology care.

At Takeda, we are committed to translating science into meaningful impact for patients, in collaboration with the broader medical community”.

The discussions during this summit focused on practical aspects of clinical practice, addressing real-world challenges faced by oncologists.

“Topics such as delivering evidence-driven cancer care for every patient, alongside evolving approaches to oncology, underscore the importance of continued medical education and regional collaboration in advancing cancer care” said, Prof. Dr. Mohamed Abdelmooti, Professor of Medical Oncology and Dean of the National Cancer Institute, Cairo University.

Prof. Dr. Graham Collins, Consultant Haematologist and Associate Professor of Haematology, Oxford University Hospitals, UK, commented, “It was inspiring to see experts from across the EAMEA region come together to discuss evolving clinical practices in Cancer Care.

This exchange of knowledge supports a multidisciplinary approach and international collaboration, which are essential to advancing patient-centered treatment and improving outcomes across different healthcare settings.

Haematological Malignancie¹ remain significant challenges in oncology, often requiring complex decision-making related to treatment sequencing and resistance management. Without timely intervention and optimized care pathways, patient prognosis can be significantly impacted.

Globally, more than 1.9 million new cases of colorectal cancer were reported in 2020, making it the third most common cancer and the second leading cause of cancer-related death.²

Hodgkin lymphoma occurs at a rate of approximately 0.98 cases per 100,000 individuals worldwide.¹

Discussions throughout the summit highlighted ongoing challenges related to equitable access to innovative treatments across the EAMEA region, alongside the need to continuously align clinical practice with emerging evidence and evolving standards of care.

Participants emphasized the value of real-world clinical experience, multidisciplinary collaboration, and increased awareness of scientific advances to support earlier diagnosis, personalized treatment planning, and improved patient outcomes.

The EAMEA Oncology summit reaffirmed Takeda’s commitment to advancing medical education, fostering collaboration with the oncology community, and supporting healthcare professionals in delivering evidence-based, patient-centered care.

Through continued investment in scientific exchange and regional collaboration, Takeda aims to contribute to shaping the future of oncology treatment and improving the lives of patients across the region.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to improve patients’ lives and their quality of life within our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

In this context, on the other hand, there are many related sector news items that you can follow. For example, we highlight the most important ones in the following list:

قد تعجبك أيضاً

اللينك المختصرللمقال: https://fintechgate.net/7a7p